Castle Biosciences Acquires AltheaDx
April 26, 2022
Castle Biosciences (Nasdaq: CSTL) completed the acquisition of AltheaDx, a San Diego-based commercial-stage pharmacogenomics company and maker of the IDgenetix mental-health PGx test. Castle paid $65.0 million in initial consideration (split $32.5M cash and $32.5M stock) and may pay up to an additional $75.0 million tied to performance and milestone achievements; AltheaDx becomes a wholly owned subsidiary and IDgenetix now has expanded Medicare coverage for multiple mental health conditions.
- Buyers
- Castle Biosciences, Inc.
- Targets
- AltheaDx, Inc.
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Castle Biosciences Acquires Cernostics
October 19, 2021
Healthcare Services
Castle Biosciences (Nasdaq: CSTL) has completed the acquisition of Cernostics, Inc., a Pittsburgh-based developer of the TissueCypher spatial biology and AI-driven image analysis platform, for approximately $30 million in initial consideration plus up to $50 million in performance-based milestones. The deal brings the TissueCypher Barrett's Esophagus Assay into Castle's portfolio, expanding the company's diagnostics capabilities into the gastrointestinal and oncology markets and adding an estimated ~$1 billion to Castle's U.S. TAM.
-
Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)
October 4, 2022
Biotechnology
Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.
-
Invitae Acquires ArcherDX to Build a Precision Oncology Genetics Platform
June 22, 2020
Healthcare Services
Invitae has entered into a definitive agreement to acquire ArcherDX in a cash-and-stock transaction valued at approximately $1.4 billion, combining Invitae's diagnostic and hereditary testing capabilities with ArcherDX's somatic genomics, liquid biopsy and bioinformatics platform. The deal is intended to integrate germline and somatic testing, expand precision oncology offerings, and accelerate adoption of comprehensive cancer genetics across clinical and biopharma customers worldwide.
-
Principle Health Systems Acquires Telos PGX
December 9, 2024
Healthcare Services
Principle Health Systems has acquired Telos PGX, a CLIA/COLA pharmacogenetic testing provider focused on the long-term care market. The acquisition adds pharmacogenetic testing capabilities to Principle's mobile diagnostic services and will keep Telos founder D.J. Hart in a leadership role to scale operations and expand PGx adoption in skilled nursing facilities.
-
OncoCyte Corporation Acquires Insight Genetics
January 10, 2020
Healthcare Services
OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.
-
ACT Genomics Acquires MC Diagnostics
August 10, 2021
Medical Devices
Taiwan-based precision medicine company ACT Genomics has acquired North Wales–headquartered molecular diagnostics specialist MC Diagnostics (MCD). The deal gives ACT Genomics access to MCD’s ALDAS microarray platform and point-of-care testing capabilities, supporting ACT’s expansion into Europe and development of additional genechip-based diagnostic products.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.